Potassium Canrenoate

Drug #589

Potassium Canrenoate is used as a potassium sparing diuretic. The actions, uses and adverse effects similar to those of spironolactone.

← Previous drug Next drug →

Primary Characteristics

It is of Semi Synthetic origin and belongs to Carboxylic acid lactone.

It belongs to Aldosterone antagonist pharmacological group on the basis of mechanism of action and also classified in Diuretic Potassium Sparing pharmacological group.

Molecular Weight: 396.2 · pK_a: 5.2 · Solubility in Water: soluble · Solubility in Alcohol: soluble · Non-proprietary name: Potassium Canrenoate.

Molecular structure of Potassium Canrenoate

Pharmacokinetics

Distribution: Potassium Canrenoate has a plasma protein binding is 98%.

Elimination: plasma half-life is 10 - 35 hr, renal excretion is 88%.

Indications

Potassium Canrenoate is primarily indicated in conditions like Magnesium deficiency, Oedema with secondary aldosteronism, Potassium deficiency, Primary hyperaldosteronism.

Contraindications

Potassium Canrenoate is contraindicated in conditions like Hyperkalaemia, Renal diseases.

Dosage

Potassium Canrenoate's dosage details are as follows:

Dose	Single Dose	Frequency	Route	Instructions
Adult Dosage
500 mg	500 mg	—	Slow IV	Over 2.5-10 Minutes
Paediatric Dosage (20kg)
0 – 0	—	—		Not recommended in this age group
Neonatal Dosage (3kg)
0 – 0	—	—		Not recommended in this age group

Drug Interactions

Unknown4 interactions

Always consult your physician for the change of dose regimen or an alternative drug of choice that may strictly be required.

Side Effects

Potassium Canrenoate in overdosage may give rise to further complications which include Deepening of voice , Hoarseness , Pitch elevation in men.

Potassium Canrenoate produces potentially life-threatening effects which include Hyperkalemia . Careful monitoring is needed with proper medical management.

The signs and symptoms that are produced after acute overdosage of Potassium Canrenoate are Restlessness , Nausea, Confusion , Vomiting, Hallucinations .

Potassium Canrenoate is known to cause more or less tolerable side effects which are usually transient. These include Gynecomastia, Menstrual irregularity, Pain at injection site.

Warnings / Precautions

Serum electrolytes and blood urea nitrogen should be measured periodically. It should be used carefully in patient who are at increased risk of developing hyperkalemia, such as elderly, those with diabetes mellitus and those with some degree of renal or hepatic impairment and patients likely to develop acidosis.

Interference in Pathology

Potassium Canrenoate may interfere in the diagnosis of Measurement of Serum Digoxin Level by radioimmunoassay , Measurement of Corticosteroid, 17-Ketosteroids, 17-OH Corticosteroids & 11-OH Corticosteroids .

Available Brands

None recorded.

Storage Conditions

Potassium Canrenoate should be stored .

Drug Classification

1.16.3 — Potassium sparing diuretics